Primary Hyperoxaluria Market Infographics
Primary Hyperoxaluria Market

Primary Hyperoxaluria


Hyperoxaluria is characterized by increased urinary excretion of oxalate. It can be caused by genetic mutations that result in oxalate overproduction (primary hyperoxaluria) or enteric hyperoxaluria, which can occur due to malabsorptive states and/or less well-understood genetic causes. Additionally, there are dietary factors that can impact urinary oxalate excretion. Primary and secondary hyperoxaluria are two distinct clinical expressions of hyperoxaluria.


Primary Hyperoxaluria Epidemiology Segmentation in the 7MM


  • Prevalent Cases of Primary Hyperoxaluria
  • Diagnosed Prevalent Cases of Primary Hyperoxaluria
  • Gender-specific Diagnosed Prevalent Cases of PrimaryHyperoxaluria
  • Age-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria
  • Type-specific DiagnosedPrevalent Cases of Primary Hyperoxaluria


Primary Hyperoxaluria Epidemiological Insights Observed in the 7MM (2021)


  • The total prevalent population of Primary Hyperoxaluria in the 7MM was estimated to be 11.9K cases.
  • The total prevalent population of Primary Hyperoxaluria in the US was found to be 8.7K cases.
  • The total diagnosed prevalent population of Primary Hyperoxaluria in the US was almost 2.3K cases.
  • The total diagnosed prevalent population of Primary Hyperoxaluria in the UK was observed to be 202 cases.
  • The total diagnosed prevalent population of Primary Hyperoxaluria in Germany was found to be 180 cases.
  • The total diagnosed prevalent population of Primary Hyperoxaluria in Japan was estimated to be 80 cases.


Primary Hyperoxaluria Market Insight


The market size of Primary Hyperoxaluria in the 7MM was found to be approximately USD 81 million in the year 2021.  


Primary Hyperoxaluria Market Drivers


  • Current and Future Changes in the Paradigm of Therapies
  • Entry of Approved Therapy
  • Future Potentials of Emerging Treatment
  • Increasing Prevalence
  • Global Exposure


Primary Hyperoxaluria Market Barriers


  • Lack of Available Long-term Data
  • Lack of Robust Pipeline
  • Delayed Diagnosis
  • Challenges in terms of management


Primary Hyperoxaluria Emerging Drugs


The emerging drugs in the Primary Hyperoxaluria market are


  • Oxabact (OC5-DB-02)
  • Nedosiran (DCR-PHXC)
  • Reloxaliase (ALLN-177)
  • Stiripentol (Diacomit), and several others


Primary Hyperoxaluria Key Players 


The key players working in the Primary Hyperoxaluria market are


  • OxThera
  • Dicerna Pharmaceuticals, Inc
  • Allena Pharmaceuticals
  • Biocodex, and many others